The GLA/α-Gal A axis: disease context and why ERT alone is insufficient

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, which encodes the enzyme α-galactosidase A (α-Gal A). Deficiency of this enzyme leads to progressive accumulation of glycosphingolipids — principally globotriaosylceramide (Gb3/GL-3) and globotriaosylsphingosine (lyso-Gb3) — in vascular endothelial cells, kidney podocytes, cardiomyocytes, and the central nervous system. Disease prevalence is estimated at approximately 1 in 40,000–60,000 males, with lower but clinically relevant penetrance in females.

The biomarker lyso-Gb3 (globotriaosylsphingosine) is cited across multiple patent records as a key plasma indicator of disease burden and treatment response. Reduction in lyso-Gb3 is used as a pharmacodynamic endpoint for migalastat, ERT, and substrate reduction therapy alike — making it a central translational anchor across all modalities.

Beyond the primary enzyme deficiency, patent records identify several secondary molecular targets. The Korea Advanced Institute of Science and Technology (KAIST) identifies TSP1 (thrombospondin-1) as a mediator of vascular endothelial dysfunction in Fabry disease, with downstream effects on phosphorylated SMAD, KDR, and eNOS proteins. A Baylor Research Institute patent proposes aberrant androgen/androgen receptor (AR) pathway signaling as a previously undescribed feature of Fabry disease — the first description of this pathway in this disease context. A cross-sectional clinical study from Necmettin Erbakan University measuring plasma α-Gal A, lyso-Gb3, periostin, proteinuria, and kidney function in 18 Fabry disease patients raises the question of whether ERT alone is sufficient to address secondary renal fibrosis driven by periostin.

According to OMIM, Fabry disease (MIM #301500) is one of the most prevalent X-linked lysosomal storage disorders. The limitations of current standard-of-care ERT — including immunogenicity, poor CNS penetration, and rapid protein degradation — are well-documented in the literature and form the central rationale for the diversified pipeline described in this analysis.

Enzyme replacement therapy: approved agents and next-generation variants

Enzyme replacement therapy (ERT) is the most frequently referenced approved modality across this patent dataset, involving intravenous infusion of purified recombinant wild-type α-Gal A. Two commercial products are referenced: agalsidase alfa (Replagal®, Shire Human Genetic Therapies) and agalsidase beta (Fabrazyme®, Sanofi Genzyme Corporation). ERT with recombinant agalsidase has been in use since 2001, according to Sangamo Therapeutics patent texts.

Limitations documented across multiple patent records include rapid protein degradation, high dosing requirements, immunogenicity (anti-GLA neutralizing antibody formation), failure to penetrate the blood-brain barrier, and insufficient accumulation in kidney podocytes and cardiomyocytes. These recognised shortcomings are the explicit rationale for next-generation ERT variants now in development.

Three distinct next-generation ERT approaches are represented in patent filings. Protalix Biotherapeutics (Israel, 2019) describes a stabilized plant-derived recombinant human α-Gal A (pegunigalsidase alfa) in which at least two α-galactosidase monomers are covalently linked via a linker moiety, enabling extended dosing intervals greater than two weeks and reduced Gb3 accumulation. Amicus Therapeutics filed a WO patent on a next-generation recombinant human α-Gal A (rha-Gal A) with a unique carbohydrate profile, claiming greater reduction in GL-3 and plasma lyso-Gb3 compared to Fabrazyme in preclinical GLA knockout mouse models. A Hanmi Pharm patent describes a therapeutic enzyme-immunoglobulin Fc fusion protein strategy for Fabry-associated kidney disease, potentially improving half-life and tissue distribution.

Oxyrane UK Limited filed patents (WO, CA, EP) on human α-N-acetylgalactosaminidase (NAGAL) polypeptide — an engineered enzyme with α-galactosidase activity derived from the NAGAL scaffold — expressed recombinantly in the yeast Yarrowia lipolytica. This offers a potential alternative ERT enzyme with improved stability for Fabry, Schindler, and Kanzaki diseases. The EP filing holds active legal status as of the dataset snapshot.

“ERT with recombinant agalsidase has been in use since 2001 — but anti-GLA neutralizing antibody formation from repeated protein infusion provides the central rationale for gene therapy as a potentially curative, single-administration approach.”

Pharmacological chaperone therapy: migalastat and the amenable mutation constraint

Pharmacological chaperone therapy is the second most represented modality in this dataset, dominated by Amicus Therapeutics, Inc. The compound migalastat — also known as 1-deoxygalactonojirimycin (1-DGJ); chemical name (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol — binds to the active site of mutant α-Gal A in the endoplasmic reticulum (ER), stabilizing it against ER-associated degradation and facilitating correct protein folding and trafficking to lysosomes, thereby increasing residual enzyme activity.

A critical limitation documented in retrieved patent records is that pharmacological chaperone therapy is only applicable to patients with “amenable mutations” — those whose GLA mutations produce a protein capable of being stabilized. Retrieved patent text explicitly states: “patients for PC therapy should have an amenable mutation or variant which results in the production of an enzyme that has the potential to be stabilized and folded into a conformation that permits trafficking out of the ER.” The HEK cell-based amenability assay is described as the key diagnostic tool for patient selection.

Multiple Amicus patents cover migalastat dosing across patient sub-populations. For patients with renal impairment, dosing is described as approximately 100–150 mg free base equivalent every other day. For pediatric patients aged 2 to less than 18 years weighing between less than approximately 15 kg and greater than approximately 50 kg, dosing is specified at approximately 15–150 mg every other day — indicating active pediatric clinical development. For ERT-experienced and ERT-naïve patients, the referenced dose is approximately 123 mg free base equivalent every other day, with endpoints including reduction in left ventricular mass index, reduction in renal GL-3, and reduction in plasma lyso-Gb3.

Meiji Pharmaceutical University (Japan) filed patents in JP and EP describing a pharmaceutical combination of a mutated α-N-acetylgalactosaminidase protein (with α-galactosidase activity) paired with an active site-specific chaperone, referencing prior clinical data demonstrating that co-administration of recombinant α-Gal A with 1-deoxygalactonojirimycin in Fabry patients stabilized the infused enzyme in blood, enhancing therapeutic effect. This ERT stabilization approach is distinct from chaperone monotherapy and represents a near-term combination opportunity that does not require new molecular entities.

According to the European Medicines Agency, pharmacological chaperone therapy represents a significant advance for patients with amenable GLA mutations who previously had no oral treatment option. The HEK amenability assay framework described in Amicus patents is a key translational tool separating eligible from ineligible patients.

Substrate reduction therapy: targeting glucosylceramide synthase upstream

Substrate reduction therapy (SRT) for Fabry disease targets glucosylceramide synthase (GCS) — the upstream enzyme in the glycosphingolipid synthesis pathway — using small molecule inhibitors to reduce biosynthesis of GL-3 substrate, thereby decreasing the amount requiring catabolism by the deficient α-Gal A. Genzyme Corporation (Sanofi) has filed two Chinese patents on GCS inhibitors that can be used alone or in combination with ERT to treat lysosomal storage diseases including Fabry disease.

Genzyme patent filings describe GCS inhibition as reducing progressive intracellular accumulation of GL-3 in kidney, heart, liver, spleen, skin, and peripheral and central nervous system. Multiple Amicus Therapeutics patent texts describe SRT as covering a class of approximately 40 LSDs that include glycosphingolipid storage disorders. A Genzyme biomarker patent (CN, 2025) identifies venglustat as an SRT agent and migalastat as a chaperone, referencing CD63 as a lysosomal dysfunction biomarker for monitoring disease progression and therapeutic intervention in Fabry disease.

The SRT + ERT combination strategy is explicitly described in Genzyme GCS inhibitor patents, which state that GCS inhibitors may be used “alone or in combination with enzyme replacement therapy,” signaling a potential synergistic substrate reduction plus enzyme replacement approach. This combination logic mirrors strategies already validated in other LSDs, as documented in the scientific literature indexed by NCBI PubMed.

mRNA and gene therapy: the nucleic acid medicine convergence

Both mRNA/LNP delivery and AAV-based gene therapy are pursuing the same underlying therapeutic rationale — restoring GLA expression — through different delivery vehicles. The concurrent patent activity in both modalities signals that the next generation of Fabry therapeutics may converge on nucleic acid medicine, potentially obviating repeated ERT infusions entirely.

mRNA/LNP: ModernaTX

ModernaTX, Inc. is the sole assignee in this dataset pursuing mRNA-based delivery of α-Gal A. Two patents (JP active, EP active) describe mRNA encoding human α-Gal A (GLA) or fusion proteins containing GLA, preferably encapsulated in lipid nanoparticles (LNPs) for efficient in vivo delivery. The therapeutic rationale is to increase and/or restore deficient GLA expression and activity, and to reduce Gb3 and lyso-Gb3 levels in subjects. These patents claim priority from a US provisional application filed in May 2016, and both hold active legal status as of the dataset snapshot.

AAV gene therapy: Sangamo and Takeda

Gene therapy using adeno-associated viral (AAV) vectors is represented by Sangamo Therapeutics and Takeda Pharmaceutical Company. Sangamo describes dosing at approximately 5×10¹² to 5×10¹³ vector genomes/kg body weight using AAV expression vectors, with therapeutic endpoints including reduced glycosphingolipid levels and increased α-Gal A protein activity. Takeda Pharmaceutical Company filed two patents (IL, 2023) on rAAV vectors packaged in AAV capsids with broad tissue tropism, encoding wild-type α-Gal A with a ubiquitous promoter, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), and poly-A signal.

Sangamo patent texts note that anti-GLA neutralizing antibody formation is a significant adverse outcome associated with repeated protein infusion, providing rationale for gene therapy as a potentially curative, single-administration approach. Both Sangamo (SG, CN filings) and Takeda (IL filings, 2023) describe broad tissue tropism as a design objective, addressing the cardiac and renal penetration limitations of conventional ERT. The concurrent activity from both companies in the same gene therapy modality signals competitive intensity in this space, as noted in analyses published by Nature on the broader rare disease gene therapy landscape.

Combination strategies and emerging precision medicine signals

Retrieved patent records reveal six distinct combination and emerging-direction signals that go beyond monotherapy development. These represent the frontier of Fabry disease drug development as captured in this patent dataset.

ERT + pharmacological chaperone co-administration: Multiple Meiji Pharmaceutical University patents (JP, EP) describe co-administration of recombinant α-Gal A with 1-deoxygalactonojirimycin (migalastat), referencing prior clinical evidence that migalastat stabilizes infused recombinant α-Gal A in blood, enhancing therapeutic effect. This is distinct from chaperone monotherapy and exploits existing approved or late-stage agents without requiring new molecular entities.

SRT + ERT combination: Genzyme GCS inhibitor patents explicitly describe GCS inhibitors for use “alone or in combination with enzyme replacement therapy,” signaling a potential synergistic substrate reduction plus enzyme replacement strategy applicable to patients who cannot benefit from migalastat due to non-amenable mutations.

Drug repurposing + agalsidase-β: A KAIST patent (EP, 2025; JP, 2025) describes selected FDA-approved, preclinical, or clinical compounds for use in combination with agalsidase-β for Fabry disease prevention or treatment, suggesting a systematic drug repurposing screen paired with standard ERT.

Kidney organoid disease models: A Catholic University of Korea patent (KR, 2025) describes patient-derived GLA-knockout kidney organoids for candidate substance screening in Fabry disease drug development. This signals that preclinical screening infrastructure for Fabry therapeutics is itself becoming a proprietary asset, with implications for research collaborations and licensing between pharmaceutical companies and academic platform holders.

Biomarker-guided therapy initiation: A Shanghai Jiao Tong University patent (CN, 2024) describes a Cox hazard model incorporating multi-center Chinese Fabry patient cohort data for predicting renal outcomes in Fabry patients, proposing its use to guide decisions on when to initiate ERT and when to add adjunct therapy. This signals an emerging precision medicine layer atop existing treatment modality choices.

Novel targets beyond substrate clearance: The KAIST TSP1 inhibition target and Baylor Research Institute AR-pathway target represent early-stage discovery opportunities with limited competitive IP density in this dataset. TSP1 knockdown in patient iPSC-derived vascular endothelial cells restored vascular morphology and signaling, providing preclinical proof-of-concept. The Baylor AR-pathway patent is described as the first description of aberrant androgen/androgen receptor pathway involvement in Fabry disease. These vascular endothelial and hormonal mechanisms may represent differentiated disease-modifying approaches particularly relevant for late-stage or ERT-inadequate patients — such as those identified in the Necmettin Erbakan clinical study showing secondary fibrotic pathology despite ERT.

The IP landscape for Fabry disease combination approaches is becoming increasingly complex. As documented in WIPO patent databases, the intersection of rare disease biology with nucleic acid medicine platforms is generating overlapping IP claims that require careful freedom-to-operate analysis, particularly as mRNA and AAV approaches mature toward the clinic. Understanding this landscape is essential for R&D strategy, licensing, and competitive intelligence decisions.

“The concurrent patent activity in mRNA/LNP (ModernaTX) and AAV gene therapy (Sangamo, Takeda) signals that the next generation of Fabry therapeutics may converge on nucleic acid medicine, potentially obviating repeated ERT infusions.”